Top

Breast Cancer

Published in:

01-11-2018 | Original Article

Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer

Authors: Tahani Louhichi, Sonia Ziadi, Hanene Saad, Myriam Ben Dhiab, Sarra Mestiri, Mounir Trimeche

Published in: Breast Cancer | Issue 6/2018

Abstract

Background

CD44 and aldehyde dehydrogenase 1 (ALDH1) has been reputed to be cancer stem cell (CSC) markers in breast cancer. Yet, the clinicopathologic and prognostic significance of these markers remain unclear. In this study, we have investigated the expression of these markers and their relation with conventional clinicopathologic tumor characteristic including molecular subtype.

Methods

CD44 and ALDH1 expression were investigated by immunohistochemistry in a series of 157 formalin-fixed paraffin-embedded breast cancer tissues.

Results

Overall, CD44 and ALDH1 are, respectively, detected in 33% (52 of 157) and 7% (10 of 157) of breast cancer cases. We also observed that CD44 expression was associated with histological grade (p = 0.005). For ALDH1, we found that its expression is more frequent with elderly women (> 50 years, p = 0.03). The investigation of relationship between the stem cell phenotype and breast cancer molecular subtype, revealed that CD44 and ALDH1 expression was more frequent in basal-like tumors (p = 0.005). Among the two cancer stem cell markers tested, ALDH1 showed a strong association with the basal marker EGFR (p = 0.05).

Conclusions

These findings suggest that CD44 and ALDH1 play a role in the clinical behavior in breast cancer and might be interesting biomarkers and therapeutic targets.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; E359–E386.CrossRefPubMed

Campbell LL, Polyak K. Breast tumors heterogeneity: cancer stem cells or clonal evolution. Cell Cycle. 2007;2332:6–8.

Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, et al. The CD44+/CD24− phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53.CrossRefPubMedPubMedCentral

Lawson JC, Blatch GL, Edkins AL. Cancer stem cells in Breast cancer and metastases. Breast Cancer Res. 2009;118:241 – 54.CrossRef

Ricardo S, Vieira AF, Gerhard R, Leitao D, Pinto R, Cameselle-Teijeiro JF, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol. 2011;64:937 – 46.CrossRefPubMed

Orian-Rousseau V. CD44, a therapeutic target for metastasin tumors. Eur J Cancer. 2010;46:1271–77.CrossRefPubMed

Bourguignon LYW, Wong G, Earle C, Krueger K, Spevak CC. Hyaluronan–CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem. 2010;285:36721–35.CrossRefPubMedPubMedCentral

Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial–mesenchymal transition and breast cancer progression. J Clin Invest. 2011;121:1064–74.CrossRefPubMedPubMedCentral

Zucchi I, Sanzone S, Astigiano S, Pelucchi P, Scotti M, Valsecchi V, et al. The properties of a mammary gland cancer stem cell. Proc Natl Acad Sci. 2007;104:10476–81.CrossRefPubMedPubMedCentral

10.

Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ, et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci. 2006;103:11707–12.CrossRefPubMedPubMedCentral

11.

Povsic TJ, Zavodni KL, Kelly FL, Zhu S, Goldschmidt-Clermont PJ, Dong C, et al. Circulating progenitor cells can be reliably identified on the basis of aldehyde dehydrogenase activity. J Am Coll Cardiol. 2007;50:2243–48.CrossRefPubMed

12.

Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cells lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69:1302–13.CrossRefPubMedPubMedCentral

13.

Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, Rochlitz C. Tumor-endothelial interaction links the CD44(+)/CD24(–) phenotype with poor prognosis in early-stage breast cancer. Neoplasia. 2009;11:987–1002.CrossRefPubMedPubMedCentral

14.

Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, et al. The clinicopathologic and prognostic significance of CD44+/CD24–/low and CD44–/CD24 + tumor cells in invasive breast carcinomas. Hum Pathol. 2008;39:1096–102.CrossRefPubMed

15.

Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24–/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005;11:1154–59.PubMed

16.

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2013;24:2206 – 223.CrossRefPubMedPubMedCentral

17.

Tan EY, Thike AA, Tan PH. ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome. Br J Cancer. 2013;109:109–13.CrossRefPubMedPubMedCentral

18.

Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol. 2010;176:2131–38.CrossRefPubMedPubMedCentral

19.

Nogami T, Shien T, Tanaka T, Nishiyama K, Mizoo T, Iwamto T, et al. Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1–3 lymph node metastases. Breast Cancer. 2012;21:58–65.CrossRefPubMed

20.

Sakakibara M, Fujimori T, Miyoshi T, Nagashima T, Fujimoto H, Suzuki HT, et al. Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer. Cancer. 2012;118:3899–910.CrossRefPubMed

21.

Dong Y, Bi LR, Xu N, Yang HM, Zhang HT, Ding Y, et al. The expression of aldehyde dehydrogenase 1 in invasive primary breast tumors and axillary lymph node metastases is associated with poor clinical prognosis. Pathol Res Pract. 2013;209:555–61.CrossRefPubMed

22.

Morimoto K, Kim SJ, Tanei T, Shimazu K, Tanji Y, Taguchi T, et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009;100:1062–68.CrossRefPubMed

23.

Kapucuoglu N, Bozkurt KK, Baspınar S, Kocer M, Eroglu HE, Akdeniz R, et al. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015;211:740–47.CrossRefPubMed

24.

Tsang JYS, Huang YH, Luo MH, Ni YB, Chan SK, Lui PCW, et al. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;136:407–17.CrossRefPubMed

25.

Chekhun SV, Zadvorny TV, Tymovska YO, Anikusko MF, Novak OE, Polishchuk LZ. CD44+/CD24− markers of cancer stem cells in patients with Breast cancer of different molecular subtypes. Exp Oncol. 2015;37:58–63.PubMed

26.

Uchoa DM, Graudenz MS, Callegari-Jacques SM, Hartmann CR, Ferreira BP, Fitarelli-Kiehl M, et al. Expression of cancer stem cell markers in basal and penta-negative breast carcinomas—a study of a series of triple-negative tumors. Pathol Res Pract. 2014;210:432 – 39.CrossRef

27.

Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med. 2015;4(9):1033–43.CrossRefPubMedPubMedCentral

28.

Makki J, Myint O, Wynn AA, Samsudin AT, John DV. Expression distribution of cancer stem cells, epithelial to mesenchymal transition, and telomerase activity in breast cancer and their association with clinicopathologic characteristics. Clin Med Insights Pathol. 2015;8:1–16.PubMedPubMedCentral

29.

Kim YS, Jung MJ, Ryu DW, Lee CH. Clinicopathologic characteristics of breast cancer stem cells identified on the basis of aldehyde dehydrogenase 1 expression. J Breast Cancer. 2014;17:121 – 28.CrossRefPubMedPubMedCentral

30.

Idowu MO, Kimeciak M, Dumu C, Burton RS, Grimes MM, Powers CN, et al. CD44+/CD24− cancer stem: progenitor cells are more abundant in triple-negative invasisve breast carcinoma phenotype and are associated with poor outcome. Hum Pathol. 2012;43:364 – 73.CrossRefPubMed

31.

De Beça FF, Caetano P, Gerhard R, Alvarenga CA, Gomes M, Paredes J, et al. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol. 2013;66:187 – 91.CrossRefPubMed

32.

Dontu G, El-Ashry D, Wisha MS. Breast cancer stem:progenitor cells and estrogen receptor. Trends Endocrinol Metab. 2004;15:193 – 97.CrossRefPubMed

33.

Liu S, Ginestier C, Charafe-Jauffret E, Focco H, Kleer CG, Merajver SD, et al. BRCA1 regulates human mammary stem:progenitor cell fate. Proc Natl Acad Sci USA. 2008;105:1680–85.CrossRefPubMedPubMedCentral

34.

Turner N, Tutt A, Ashworth A. Hallmarks of “BRCAness” in sporadic cancers. Nat Rev Cancer. 2004;4:814–19.CrossRefPubMed

35.

Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004;14:43–7.CrossRefPubMed

36.

Sahin IH, Klostergaard J. CD44 as a drug delivery target in human cancers: where are we now? Expert Opin Ther Targets. 2015;16:1–5.

Title: Clinicopathological significance of cancer stem cell markers CD44 and ALDH1 expression in breast cancer
Authors: Tahani Louhichi
Sonia Ziadi
Hanene Saad
Myriam Ben Dhiab
Sarra Mestiri
Mounir Trimeche
Publication date: 01-11-2018
Publisher: Springer Japan
Published in: Breast Cancer / Issue 6/2018
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-018-0875-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

MiR-1301-3p inhibits human breast cancer cell proliferation by regulating cell cycle progression and apoptosis through directly targeting ICT1

The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer

Artesunate promotes G2/M cell cycle arrest in MCF7 breast cancer cells through ATM activation

Comparison of Ki-67 labeling index measurements using digital image analysis and scoring by pathologists

Real-time navigation system for sentinel lymph node biopsy in breast cancer patients using projection mapping with indocyanine green fluorescence

A randomized phase II study evaluating pyridoxine for the prevention of hand–foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer